false
0001494891
0001494891
2024-05-09
2024-05-09
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
DC 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of Report (Date of earliest event reported): May 9, 2024
SENSUS HEALTHCARE, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
001-37714 |
|
27-1647271 |
| (State
of Incorporation) |
|
(Commission
File Number) |
|
(IRS
Employer
Identification No.) |
851 Broken Sound Pkwy., NW # 215, Boca Raton, Florida |
|
33487 |
| (Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (561) 922-5808
(Former
Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| ☐ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ | Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common Stock, par value $0.01 per share |
|
SRTS |
|
Nasdaq Stock Market, LLC |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
SENSUS
HEALTHCARE, INC.
FORM
8-K
CURRENT
REPORT
Item 2.02 Results of Operation and Financial Condition
On
May 9, 2024, Sensus Healthcare, Inc. announced via press release its financial results for the first quarter of 2024. A copy of the press
release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.
The
press release makes reference to certain non-GAAP financial measures. A reconciliation of the non-GAAP financial measures and other financial
information is provided in the press release.
The
information furnished under Item 2.02, including in Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18
of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933,
except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d)
Exhibits
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
| |
SENSUS HEALTHCARE, INC. |
| |
|
|
| Date:
May 9, 2024 |
By: |
/s/
Javier Rampolla |
| |
|
Javier
Rampolla |
| |
|
Chief
Financial Officer |
EXHIBIT
INDEX
3
Exhibit 99.1
Sensus Healthcare Reports First Quarter 2024 Financial
Results With Revenues up More than Three-fold
| · | Revenues of $10.7 million, compared with $3.4 million in the prior-year quarter; Adjusted EBITDA
(a non-GAAP measure) of $3.0 million, compared with negative $2.7 million in the prior-year quarter |
| · | Launched the “Fair Deal Agreement” recurring revenue program to provide an equipment
placement option and complement the fair market value lease program for SRT systems |
Conference call begins at 4:30 p.m. Eastern
time today
BOCA RATON, Fla. (May 9, 2024) – Sensus Healthcare,
Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective
treatments for oncological and non-oncological conditions, announces financial results for the three months ended March 31, 2024.
Highlights from the first quarter of 2024 and recent
weeks include the following (all comparisons are with the first quarter of 2023, unless otherwise noted):
| · | Revenues were $10.7 million, compared with $3.4 million, an increase of 214%, reflecting higher superficial
radiotherapy (SRT and IG-SRT) unit sales |
| · | Shipped 26 systems, compared with 10 systems |
| · | Net income was $2.3 million, or $0.14 per diluted share, compared with a net loss of $1.9 million, or
$0.12 per share |
| · | Ended the quarter with $14.7 million in cash and cash equivalents, and no debt |
| · | Accounts receivable as of March 31, 2024 were $19.6 million, compared with $10.6 million as of December
31, 2023 |
| · | Continued to build inventories to prepare for anticipated customer demand |
| · | Launched “Fair Deal Agreement” recurring revenue program for the SRT-100 Vision™ (IG-SRT) |
| · | Showcased all products and services at the Winter Clinical and South Beach Symposium, and at the American
Academy of Dermatology Annual Meeting |
| · | Engaged CureRays to provide oversight and supervision for customers involved with the recurring revenue
program and to enhance patient safety; CureRays will also conduct clinical studies to expand indications for SRT, beginning with inflammatory
diseases |
| · | Issued a U.S. patent for SRT-100 Vision System (IG-SRT) treatment planning capabilities |
| · | Sold first SRT-100 Vision System (IG-SRT) in Asia, to Far Eastern Memorial Hospital in Taiwan |
| | · | Made first commercial sale of an
SRT-100 for veterinary use outside the U.S., to Chavat Da’at, the Veterinary Specialist Referral Center Knowledge Farm at Beit
Verl College in Tel Aviv, to provide a gentler radiotherapy option to treat tumors in dogs and cats |
Management Commentary
“Our first quarter financial results were strong
as we more than tripled revenues compared with the 2023 quarter and achieved a substantial profit, reversing last year’s net loss
as customers adjust to macroeconomic conditions,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “This
performance reflects continued business momentum as customers recognize the importance to their patients of SRT, a non-invasive and highly
efficacious modality to treat non-melanoma skin cancer, while benefitting from a choice in sales options, including our new Fair Deal
Agreement to complement our proven fair market value lease program.
“We showcased our Fair Deal Agreement program
at three important trade conferences during the quarter, including the Winter Clinical and South Beach Symposium, and the American Academy
of Dermatology Annual Meeting. We enjoyed excellent booth traffic at all three events. The Fair Deal Agreement is a recurring revenue
program that addresses the customer’s need to use capital in other areas of growing their business, and facilitates what we believe
is a compelling economic model. This new offering continues to gain traction with more and more interest each and every day. Under this
program, the more patients treated with SRT-100 Vision, the more revenue to the practice. It’s that simple. The Fair Deal Agreement
includes the work of CureRays to provide oversight to facilitate the utmost efficiency and effectiveness of the dermatology practice.”
Mr. Sardano added, “In addition to launching
the Fair Deal Agreement, at these trade shows we also showcased the state-of-the-art capabilities embedded in the SRT-100 Vision. These
include our newly patented proprietary technology covering 33 individual claims. The patent describes technology that’s essentially
a treatment-planning system made possible by fusing a radiation therapy device with high-frequency ultrasound, permitting seamless operation
with the Fair Deal Agreement program.
“Between interest in the new technology and
our new sales offering, we have assembled a significant pipeline of potential customers, so much so that we built further inventory to
satisfy anticipated demand,” Mr. Sardano continued. “That said, we highly value our existing customers and continue to work
with them to expand SRT to additional clinics nationwide.
“Our goal is to make SRT the standard of care
for treating non-melanoma skin cancer and keloids. We believe we have barely penetrated this market and see plenty of room for growth,
both in the U.S. and around the world, as evidenced by recent progress in Taiwan,” Mr. Sardano concluded.
First Quarter Financial Results
Revenues for the first quarter of 2024 were $10.7
million, compared with $3.4 million for the first quarter of 2023, an increase of $7.3 million, or 215%. The increase was primarily driven
by a higher number of SRT systems sold to a large customer.
Cost of sales was $4.0 million for the first quarter
of 2024, compared with $1.8 million for the prior-year quarter, an increase of $2.2 million, or 122%. The increase was primarily related
to a higher number of units sold.
Gross profit for the first quarter of 2024 was $6.7
million, or 62.5% of revenues, compared with $1.6 million, or 47.5% of revenues, for the first quarter of 2023, an increase of $5.1 million,
or 319%. The increase was primarily driven by the increased number of units sold.
Selling and marketing expense was $1.3 million for
the first quarter of 2024, compared with $2.1 million for the prior-year quarter, a decrease of $0.8 million, or 38%. The decrease was
primarily attributable to a decline in marketing expense, headcount and tradeshow costs.
General and administrative expense was $1.6 million
for the first quarter of 2024, compared with $1.4 million for the first quarter of 2023, an increase of $0.2 million, or 14%. The increase
was primarily due to higher professional fees and compensation.
Research and development expense was $0.9 million
for the first quarter of 2024, compared with $1.1 million for the first quarter of 2023, a decrease of $0.2 million, or 18%. The decrease
reflects the completion of development of a drug delivery system for the aesthetic market.
Other income of $0.2 million for the first quarter
of 2024 was mostly related to interest income, and was unchanged from the prior-year quarter.
Net income for the first quarter of 2024 was $2.3
million, or $0.14 per diluted share, compared with a net loss of $1.9 million, or $0.12 per share, for the first quarter of 2023.
Adjusted EBITDA for the first quarter of 2024 was
$3.0 million, compared with negative $2.7 million for the first quarter of 2023. Adjusted EBITDA, a non-GAAP financial measure, is defined
as earnings before interest, taxes, depreciation, amortization and stock-compensation expense. Please see below for a reconciliation between
GAAP and non-GAAP financial measures, and the reasons these non-GAAP financial measures are provided.
Cash and cash equivalents were $14.7 million as of
March 31, 2024, compared with $23.1 million as of December 31, 2023. The Company had no outstanding borrowings under its revolving line
of credit. Accounts receivable were $19.6 million as of March 31, 2024, compared with $10.6 million as of December 31, 2023. Prepaid inventory
was $3.7 million, compared with $3.0 million, and inventories were $14.7 million, compared with $11.9 million, reflecting preparations
for higher expected unit sales and placements in 2024.
Use of Non-GAAP Financial Information
This press release contains supplemental financial
information determined by methods other than in accordance with accounting principles generally accepted in the United States (GAAP).
Sensus Healthcare management uses Adjusted EBITDA, a non-GAAP financial measure, in its analysis of the Company’s performance. Adjusted
EBITDA should not be considered a substitute for GAAP basis measures, nor should it be viewed as a substitute for operating results determined
in accordance with GAAP. Management believes the presentation of Adjusted EBITDA, which excludes the impact of interest, income taxes,
depreciation, amortization and stock-compensation expense, provides useful supplemental information that is essential to a proper understanding
of the financial results of Sensus Healthcare. Non-GAAP financial measures are not formally defined by GAAP, and other entities may use
calculation methods that differ from those used by Sensus Healthcare. As a complement to GAAP financial measures, management believes
that Adjusted EBITDA assists investors who follow the practice of some investment analysts who adjust GAAP financial measures to exclude
items that may obscure underlying performance and distort comparability. A reconciliation of the GAAP net loss to Adjusted EBITDA is provided
in the schedule below.
SENSUS HEALTHCARE, INC.
GAAP TO NON-GAAP RECONCILIATION
(unaudited)
| | |
For the Three Months Ended | |
| | |
March 31, | |
| (in thousands) | |
2024 | | |
2023 | |
| Net income (loss), as reported | |
$ | 2,274 | | |
$ | (1,894 | ) |
| Add: | |
| | | |
| | |
| Depreciation and amortization | |
| 70 | | |
| 72 | |
| Stock compensation expense | |
| 91 | | |
| 143 | |
| Income tax expense (benefit) | |
| 827 | | |
| (802 | ) |
| Interest income, net | |
| (214 | ) | |
| (243 | ) |
| Adjusted EBITDA, non GAAP | |
$ | 3,048 | | |
$ | (2,724 | ) |
Conference
Call and Webcast
Sensus
Healthcare will host an investment community conference call today beginning at 4:30 p.m. Eastern time during which management will discuss
financial results for the 2024 first quarter, provide a business update and answer questions. To access the conference call, dial 844-481-2811
(U.S. and Canada Toll Free) or 412-317-0676 (International). The call will be webcast live and can be accessed at this link,
or in the Investors section of the Company’s website at www.sensushealthcare.com.
Following
the conclusion of the conference call, a replay will be available until June 9, 2024 and can be accessed by dialing 877-344-7529 (U.S.
Toll Free), 855-669-9658 (Canada Toll Free) or 412-317-0088 (International), using replay code 9785929. An archived webcast of the call
will also be available in the Investors section of the Company’s website.
About
Sensus Healthcare
Sensus
Healthcare, Inc. is a global pioneer in the development and delivery of non-invasive treatments for skin cancer and keloids. Leveraging
its cutting-edge superficial radiotherapy (SRT and IG-SRT) technology, the company provides healthcare providers with a highly effective,
patient-centric treatment platform. With a dedication to driving innovation in radiation oncology, Sensus Healthcare offers solutions
that are safe, precise, and adaptable to a variety of clinical settings. For more information, please visit www.sensushealthcare.com.
Forward-Looking
Statements
This
press release includes statements that are, or may be deemed, ’‘forward-looking statements.’’ In some cases, these statements can be
identified by the use of forward-looking terminology such as “believes,” “estimates,” “anticipates,” “expects,”
“plans,” “intends,” “may,” “could,” “might,” “will,” “should,”
“approximately,” “potential” or negative or other variations of those terms or comparable terminology, although
not all forward-looking statements contain these words.
Forward-looking
statements involve risks and uncertainties because they relate to events, developments, and circumstances relating to Sensus, our industry,
and/or general economic or other conditions that may or may not occur in the future or may occur on longer or shorter timelines or to
a greater or lesser degree than anticipated. In addition, even if future events, developments, and circumstances are consistent with
the forward-looking statements contained in this press release, they may not be predictive of results or developments in future periods.
Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, forward-looking
statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ materially from the forward looking statements contained in this press release,
as a result of the following factors, among others: our ability to maintain profitability; our ability to sell the number of SRT units
we anticipate for the balance of 2024; the possibility that inflationary pressures continue to impact our sales; the level and availability
of government and/or third party payor reimbursement for clinical procedures using our products, and the willingness of healthcare providers
to purchase our products if the level of reimbursement declines; the regulatory requirements applicable to us and our competitors; our
ability to efficiently manage our manufacturing processes and costs; the risks arising from doing business in China and other foreign
countries; legislation, regulation, or other governmental action that affects our products, taxes, international trade regulation, or
other aspects of our business; concentration of our customers in the U.S. and China, including the concentration of sales to one particular
customer in the U.S.; the performance of the Company’s information technology systems and its ability to maintain data security;
our ability to obtain and maintain the intellectual property needed to adequately protect our products, and our ability to avoid infringing
or otherwise violating the intellectual property rights of third parties; and other risks described from time to time in our filings
with the Securities and Exchange Commission, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.
To
date, we do not expect that the Middle East conflict, the Russian invasion of Ukraine and global geopolitical uncertainty have had any
particular impact on our business, but we continue to monitor developments and will address them in future disclosures, if applicable.
Any
forward-looking statements that we make in this press release speak only as of the date of such statement, and we undertake no obligation
to update such statements to reflect events or circumstances after the date of this press release, except as may be required by applicable
law. You should read carefully our “Introductory Note Regarding Forward-Looking Information” and the factors described in the
“Risk Factors” section of our periodic reports filed with the Securities and Exchange Commission to better understand the risks
and uncertainties inherent in our business.
Contact:
LHA Investor Relations
Kim
Sutton Golodetz
212-838-3777
kgolodetz@lhai.com
(Tables
to follow)
SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
| | |
For the Three Months Ended | |
| | |
March 31, | |
| (in thousands, except share and per share data) | |
2024 | | |
2023 | |
| | |
(unaudited) | | |
(unaudited) | |
| Revenues | |
$ | 10,663 | | |
$ | 3,414 | |
| Cost of sales | |
| 4,001 | | |
| 1,792 | |
| Gross profit | |
| 6,662 | | |
| 1,622 | |
| Operating expenses: | |
| | | |
| | |
| Selling and marketing | |
| 1,270 | | |
| 2,099 | |
| General and administrative | |
| 1,579 | | |
| 1,364 | |
| Research and development | |
| 926 | | |
| 1,098 | |
| Total operating expenses | |
| 3,775 | | |
| 4,561 | |
| Income (loss) from operations | |
| 2,887 | | |
| (2,939 | ) |
| Other income: | |
| | | |
| | |
| Interest income, net | |
| 214 | | |
| 243 | |
| Other income, net | |
| 214 | | |
| 243 | |
| Income (loss) before income tax | |
| 3,101 | | |
| (2,696 | ) |
| Provision for (benefit from) income tax | |
| 827 | | |
| (802 | ) |
| Net Income (loss) | |
$ | 2,274 | | |
$ | (1,894 | ) |
| Net income (loss) per share – basic | |
$ | 0.14 | | |
$ | (0.12 | ) |
| – diluted | |
$ | 0.14 | | |
$ | (0.12 | ) |
| Weighted average number of shares used in computing net income (loss) per share – basic | |
| 16,294,970 | | |
| 16,245,343 | |
| – diluted | |
| 16,318,047 | | |
| 16,245,343 | |
SENSUS HEALTHCARE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
| | |
As of
March 31, | | |
As of
December 31, | |
| (in thousands, except shares and per share data) | |
2024 | | |
2023 | |
| | |
(unaudited) | | |
| |
| Assets | |
| | |
| |
| Current assets | |
| | |
| |
| Cash and cash equivalents | |
$ | 14,728 | | |
$ | 23,148 | |
| Accounts receivable, net | |
| 19,625 | | |
| 10,645 | |
| Inventories | |
| 14,720 | | |
| 11,861 | |
| Prepaid inventory | |
| 3,671 | | |
| 2,986 | |
| Other current assets | |
| 1,169 | | |
| 888 | |
| Total current assets | |
| 53,913 | | |
| 49,528 | |
| Property and equipment, net | |
| 633 | | |
| 464 | |
| Deferred tax asset | |
| 1,313 | | |
| 2,140 | |
| Operating lease right-of-use assets, net | |
| 726 | | |
| 774 | |
| Other noncurrent assets | |
| 688 | | |
| 804 | |
| Total assets | |
$ | 57,273 | | |
$ | 53,710 | |
| Liabilities and stockholders’ equity | |
| | | |
| | |
| Current liabilities | |
| | | |
| | |
| Accounts payable and accrued expenses | |
$ | 3,703 | | |
$ | 2,793 | |
| Product warranties | |
| 594 | | |
| 538 | |
| Operating lease liabilities, current portion | |
| 191 | | |
| 187 | |
| Income tax payable | |
| 37 | | |
| 37 | |
| Deferred revenue, current portion | |
| 948 | | |
| 657 | |
| Total current Liabilities | |
| 5,473 | | |
| 4,212 | |
| Operating lease liabilities, net of current portion | |
| 553 | | |
| 596 | |
| Deferred revenue, net of current portion | |
| 40 | | |
| 60 | |
| Total liabilities | |
| 6,066 | | |
| 4,868 | |
| Commitments and contingencies | |
| | | |
| | |
| Stockholders’ equity | |
| | | |
| | |
| Preferred stock, 5,000,000 shares authorized and none issued and outstanding | |
| - | | |
| - | |
| Common stock, $0.01 par value – 50,000,000 authorized; 16,925,595 issued and 16,392,671 outstanding at March 31, 2024; 16,907,095 issued and 16,374,171 outstanding at December 31, 2023 | |
| 169 | | |
| 169 | |
| Additional paid-in capital | |
| 45,496 | | |
| 45,405 | |
| Treasury stock, 532,924 shares at cost, at March 31, 2024 and December 31, 2023 | |
| (3,519 | ) | |
| (3,519 | ) |
| Retained earnings | |
| 9,061 | | |
| 6,787 | |
| Total stockholders’ equity | |
| 51,207 | | |
| 48,842 | |
| Total liabilities and stockholders’ equity | |
$ | 57,273 | | |
$ | 53,710 | |
7
v3.24.1.u1
Cover
|
May 09, 2024 |
| Cover [Abstract] |
|
| Document Type |
8-K
|
| Amendment Flag |
false
|
| Document Period End Date |
May 09, 2024
|
| Entity File Number |
001-37714
|
| Entity Registrant Name |
SENSUS HEALTHCARE, INC.
|
| Entity Central Index Key |
0001494891
|
| Entity Tax Identification Number |
27-1647271
|
| Entity Incorporation, State or Country Code |
DE
|
| Entity Address, Address Line One |
851 Broken Sound Pkwy.
|
| Entity Address, Address Line Two |
NW # 215
|
| Entity Address, City or Town |
Boca Raton
|
| Entity Address, State or Province |
FL
|
| Entity Address, Postal Zip Code |
33487
|
| City Area Code |
561
|
| Local Phone Number |
922-5808
|
| Written Communications |
false
|
| Soliciting Material |
false
|
| Pre-commencement Tender Offer |
false
|
| Pre-commencement Issuer Tender Offer |
false
|
| Title of 12(b) Security |
Common Stock, par value $0.01 per share
|
| Trading Symbol |
SRTS
|
| Security Exchange Name |
NASDAQ
|
| Entity Emerging Growth Company |
false
|
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 2 such as Street or Suite number
| Name: |
dei_EntityAddressAddressLine2 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
Grafico Azioni Sensus Healthcare (NASDAQ:SRTS)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Sensus Healthcare (NASDAQ:SRTS)
Storico
Da Gen 2024 a Gen 2025
